FLT3 and leukemia: We focused our efforts on FLT3ITD, FLT3N676K, and NRASG12D, as FLT3 and NRAS are the most common targets of mutations that deregulate signal transduction in AML, and studied clonal evolution of leukemia cells carrying subclonal activating mutations over time.